Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

INTRODUCTION: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab (NI) versus pemetrexed plus cisplatin/carboplatin (C) as the first-line treatment for unresectable malignant pleural mesothelioma (MPM) from the perspective of US payers. METHODS: A 10-year partitioned survival mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Liu, Cao, Xueqiong, Li, Na, Zheng, Bin, Liu, Maobai, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358333/
https://www.ncbi.nlm.nih.gov/pubmed/35958872
http://dx.doi.org/10.1177/17588359221116604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358333/
https://www.ncbi.nlm.nih.gov/pubmed/35958872
http://dx.doi.org/10.1177/17588359221116604

Ejemplares similares